Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The polymerized protein response (PPR) is activated by genetic variants that polymerize in the ER and is mediated by NFκBp50.

Nature communications·2026
Same author

A pathogenic Tau mutation drives autophagy-lysosome dysfunction that limits Tau degradation in a model of frontotemporal dementia.

Nature communications·2026
Same author

Phenotypic expansion of CALM1/2-associated disorders to include neurologic phenotypes without arrhythmia.

Human molecular genetics·2025
Same author

Null Mutant <i>mig-15(udn323)</i> Shows Touch Receptor Neuron Migration Defects in <i>C. elegans</i>.

microPublication biology·2025
Same author

Sequelae and reversal of age-dependent alterations in mitochondrial dynamics via autophagy enhancement in reprogrammed human neurons.

bioRxiv : the preprint server for biology·2025
Same author

ATG-3 limits Orsay virus infection in C. elegans and regulates collagen pathways.

PLoS pathogens·2025

Related Experiment Video

Updated: May 4, 2026

Automated Behavioral Analysis of Large C. elegans Populations Using a Wide Field-of-view Tracking Platform
07:20

Automated Behavioral Analysis of Large C. elegans Populations Using a Wide Field-of-view Tracking Platform

Published on: November 28, 2018

10.6K

C. elegans in high-throughput drug discovery.

Linda P O'Reilly1, Cliff J Luke1, David H Perlmutter1

  • 1Department of Pediatrics, Cell Biology and Physiology, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh of UPMC, 4401 Penn Avenue, Pittsburgh, PA 15224,USA.

Advanced Drug Delivery Reviews
|December 17, 2013
PubMed
Summary
This summary is machine-generated.

Caenorhabditis elegans is a powerful model for studying human diseases and discovering new drugs. Advances in technology now enable automated, high-throughput drug screening using this versatile organism.

Keywords:
Clozapine (PubChem CID: 2818)Drug target identificationFluphenazine (PubChem CID: 3372)High-throughput screeningHuman disease modelsNemadipine-A (PubChem CID: 2856102)PharmaceuticalsPhenotypic analysisSmall moleculesWhole organism model

More Related Videos

Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans
10:58

Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans

Published on: February 27, 2012

20.1K
A High-throughput, High-content, Liquid-based C. elegans Pathosystem
09:44

A High-throughput, High-content, Liquid-based C. elegans Pathosystem

Published on: July 1, 2018

14.2K

Related Experiment Videos

Last Updated: May 4, 2026

Automated Behavioral Analysis of Large C. elegans Populations Using a Wide Field-of-view Tracking Platform
07:20

Automated Behavioral Analysis of Large C. elegans Populations Using a Wide Field-of-view Tracking Platform

Published on: November 28, 2018

10.6K
Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans
10:58

Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans

Published on: February 27, 2012

20.1K
A High-throughput, High-content, Liquid-based C. elegans Pathosystem
09:44

A High-throughput, High-content, Liquid-based C. elegans Pathosystem

Published on: July 1, 2018

14.2K

Area of Science:

  • Biomedical research
  • Genomics and proteomics
  • Pharmacology

Background:

  • Caenorhabditis elegans serves as a valuable model organism for understanding human diseases at molecular and cellular levels.
  • Its application has expanded into drug discovery, leveraging its biological simplicity and genetic tractability.

Purpose of the Study:

  • To review the evolution of drug screening using Caenorhabditis elegans.
  • To discuss challenges associated with C. elegans-based drug discovery.
  • To highlight technological advancements enabling high-throughput screening.

Main Methods:

  • Review of existing literature on C. elegans drug screening.
  • Analysis of technological progress in liquid handling, imaging, and data analysis.
  • Discussion of challenges and future directions in the field.

Main Results:

  • C. elegans drug screening has evolved from labor-intensive methods to automated, high-throughput approaches.
  • Recent technological innovations have significantly improved the efficiency and viability of C. elegans for drug discovery.
  • Key challenges remain, but are being addressed by ongoing technological advancements.

Conclusions:

  • Caenorhabditis elegans is increasingly recognized as a viable and powerful model for automated high-throughput drug discovery.
  • Technological progress is overcoming previous limitations, paving the way for future drug screens.
  • The organism's utility in disease modeling and drug development is expected to grow.